162 related articles for article (PubMed ID: 33850485)
1. Comparison of radioiodine ablation rates between low
Norouzi G; Shafiei B; Hadaegh F; Qutbi M; Asli IN; Jafari E; Javadi H; Assadi M
World J Nucl Med; 2021; 20(1):17-22. PubMed ID: 33850485
[TBL] [Abstract][Full Text] [Related]
2. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial.
Fallahi B; Beiki D; Takavar A; Fard-Esfahani A; Gilani KA; Saghari M; Eftekhari M
Nucl Med Commun; 2012 Mar; 33(3):275-82. PubMed ID: 22124360
[TBL] [Abstract][Full Text] [Related]
3. Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer.
Abe K; Ishizaki U; Ono T; Horiuchi K; Kanaya K; Sakai S; Okamoto T
Ann Nucl Med; 2020 Feb; 34(2):144-151. PubMed ID: 31834567
[TBL] [Abstract][Full Text] [Related]
4. Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer.
Lv RB; Wang QG; Liu C; Liu F; Zhao Q; Han JG; Ren DL; Liu B; Li CL
Onco Targets Ther; 2017; 10():4051-4057. PubMed ID: 28860813
[TBL] [Abstract][Full Text] [Related]
5. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
6. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
[TBL] [Abstract][Full Text] [Related]
8. DELAYED 131-I FIRST TREATMENT AFTER SURGERY HAS NO IMPACT ON THE MEDIAN TERM OUTCOME OF PATIENTS WITH INTERMEDIATE RISK DIFFERENTIATED THYROID CANCER.
Matrone A; Gambale C; Torregrossa L; Piaggi P; Bianchi F; Valerio L; Viola D; Agate L; Molinaro E; Materazzi G; Basolo F; Vitti P; Elisei R
Endocr Pract; 2020 Jan; 26(1):58-71. PubMed ID: 31557080
[No Abstract] [Full Text] [Related]
9. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
10. Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients.
Tatar FA; Morita E; Ituarte PH; Cavalieri RR; Duh QY; Price DC; Siperstein AE; Clark OH
World J Surg; 2001 Jun; 25(6):718-22. PubMed ID: 11376405
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine lobar ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer.
Bal CS; Kumar A; Pant GS
Nucl Med Commun; 2003 Feb; 24(2):203-8. PubMed ID: 12548045
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi.
Kukulska A; Krajewska J; Gawkowska-Suwińska M; Puch Z; Paliczka-Cieslik E; Roskosz J; Handkiewicz-Junak D; Jarzab M; Gubała E; Jarzab B
Thyroid Res; 2010 Nov; 3(1):9. PubMed ID: 21040579
[TBL] [Abstract][Full Text] [Related]
13. Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary.
Domínguez JM; Nilo F; Contreras T; Carmona R; Droppelmann N; González H; Iturrieta V; Tuttle RM
J Ultrasound Med; 2017 Nov; 36(11):2299-2307. PubMed ID: 28543974
[TBL] [Abstract][Full Text] [Related]
14. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial.
Jin Y; Ruan M; Cheng L; Fu H; Liu M; Sheng S; Chen L
Thyroid; 2019 Jan; 29(1):101-110. PubMed ID: 30560716
[TBL] [Abstract][Full Text] [Related]
16. Radioiodine remnant ablation in low-risk differentiated thyroid cancer.
Saengsuda Y
J Med Assoc Thai; 2013 May; 96(5):614-24. PubMed ID: 23745318
[TBL] [Abstract][Full Text] [Related]
17. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
Giovanella L; Ceriani L; Ghelfo A; Keller F; Sacchi A; Maffioli M; Spriano G
Clin Chem Lab Med; 2006; 44(5):648-52. PubMed ID: 16681439
[TBL] [Abstract][Full Text] [Related]
18. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
Stevic I; Dembinski TC; Pathak KA; Leslie WD
Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer.
Ha S; Oh SW; Kim YK; Koo do H; Jung YH; Yi KH; Chung JK
J Korean Med Sci; 2015 Jul; 30(7):876-81. PubMed ID: 26130949
[TBL] [Abstract][Full Text] [Related]
20. [Differentiated thyroid carcinoma--how to improve the long-term results? Twenty-five-year outcomes of 850 patients].
Melliere D; Hindie E; Becquemin JP; Desgranges P; Allaire E; Geachan E
Bull Acad Natl Med; 2006 Jan; 190(1):89-106; discussion 106-9. PubMed ID: 16878448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]